Establishment of an in vivo meningioma model with human telomerase reverse transcriptase

Neurosurgery

Volumn 60, Issue 4, 2007, Pages 750-759

  Cargioli, Theresa G ^a   Ugur, Hasan C ^b   Ramakrishna, Naren ^a   Chan, Jennifer ^a   Black, Peter M ^a   Carroll, Rona S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Meningioma; Model; Telomerase; Therapeutics

Indexed keywords

BUTYRIC ACID; HYDROXYUREA; TELOMERASE REVERSE TRANSCRIPTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL IMMORTALIZATION; CELL LINE; CONTROLLED STUDY; DISEASE MODEL; DRUG INHIBITION; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN VIVO STUDY; KARYOTYPING; KINETICS; MALE; MENINGIOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TISSUE CULTURE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MALE; MENINGIOMA; MICE; MICE, NUDE; TELOMERASE; TRANSFECTION;

EID: 34147203100     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000255397.00410.8F     Document Type: Article

References (55)

1. Artlich A, Schmidt D: Immunohistochemical profile of meningiomas and their histological subtypes. Hum Pathol 21:843-849, 1990.
2. Baia GS, Slocum AL, Hyer JD, Misra A, Sehati N, VandenBerg SR, Feuerstein BG, Deen DF, McDermott MW, Lal A: A genetic strategy to overcome the senescence of primary meningioma cell cultures. J Neurooncol 78:113-121, 2006.
3. Berridge MV, Tan AS: Characterization of the cellular reduction of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT): Subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys 303:474-482, 1993.
4. Black PM: Meningiomas. Neurosurgery 32:643-657, 1993.
5. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE: Extension of life-span by introduction of telomerase into normal human cells. Science 279:349-352, 1998.
6. Boldrini L, Pistolesi S, Gisfredi S, Ursino S, Lupi G, Caniglia M, Pingitore R, Basolo F, Parenti G, Fontanini G: Telomerase in intracranial meningiomas. Int J Mol Med 12:943-947, 2003.
7. Cabuy E, de Ridder L: Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo. Virchows Arch 439:176-184, 2001.
8. Carroll RS, Glowacka D, Dashner K, Black PM: Progesterone receptor expression in meningiomas. Cancer Res 53:1312-1316, 1993.
9. Carroll RS, Zhang J, Dashner K, Black PM: Progesterone and glucocorticoid receptor activation in meningiomas. Neurosurgery 37:92-97, 1995.
10. Central Brain Tumor Registry of the United States: Statistical Report: Primary Brain Tumors in the United States, 1997-2001. Chicago, Central Brain Tumor Registry of the United States, 2004, p18.
11. Cerda-Nicolas M, Lopez-Gines C, Perez-Bacete M, Barcia-Salorio JL, Llombart-Bosch A: Histopathological and cytogenetic findings in benign, atypical and anaplastic human meningiomas: A study of 60 tumors. J Neurooncol 47:99-108, 2000.
12. Chamberlain MC, Blumenthal DT: Intracranial meningiomas: Diagnosis and treatment. Expert Rev Neurother 4:641-648, 2004.
13. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM: Epidemiology of intracranial meningioma. Neurosurgery 57:1088-1095, 2005.
14. Engelhard HH, Duncan HA, Kim S, Criswell PS, Van Eldik L: Therapeutic effects of sodium butyrate on glioma cells in vitro and in the rat C6 glioma model. Neurosurgery 48:616-625, 2001.
15. Falchetti ML, Larocca LM, Pallini R: Telomerase in brain tumors. Childs Nerv Syst 18:112-117, 2002.
16. Feurer DJ, Weller RO: Barrier functions of the leptomeninges: Astudy of normal meninges and meningiomas in tissue culture. Neuropathol Appl Neurobiol 17:391-405, 1991.
17. Gutmann DH, Giovannini M: Mouse models of neurofibromatosis 1 and 2. Neoplasia 4:279-290, 2002.
18. Hahn WC, Weinberg RA: Rules for making human tumor cells. N Engl J Med 347:1593-1603, 2002.
19. Haines L, Korf BR, Morton CC, Seidman CE, Seidman JG, Smith DR: Microscopy and image analysis, in McNamara G, Difilippanonio MJ, Reid T (eds.): Current Protocols in Human Genetics. Hoboken, John Wiley & Sons, 2006, pp 4.01-4.13.
20. Hancq S, Salmon I, Brotchi J, De Witte O, Gabius HJ, Heizmann CW, Kiss R, Decaestecker C: S100A5: A marker of recurrence in WHO grade I meningiomas. Neuropathol Appl Neurobiol 30:178-187, 2004.
21. Jensen RL, Leppla D, Rokosz N, Wurster RD: Matrigel augments xenograft transplantation of meningioma cells into athymic mice. Neurosurgery 42:130-136, 1998.
22. Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G, Gutmann DH, Giovannini M: Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 16:1060-1065, 2002.
23. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H: Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578-3588, 2003.
24. Korsgaard R, Clausen OP, Thorud E: Establishment of a human meningeal cell line in culture. Anticancer Res 4:83-89, 1984.
25. Krakoff IH, Brown NC, Reichard P: Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res 28:1559-1565, 1968.
26. Lamszus K: Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 63:275-286, 2004.
27. Lee WH: Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee. Neurosurgery 27:389-396, 1990.
28. Leuraud P, Dezamis E, Aguirre-Cruz L, Taillibert S, Lejeune J, Robin E, Mokhtari K, Boch AL, Cornu P, Delattre JY, Sanson M: Prognostic value of allelic losses and telomerase activity in meningiomas. J Neurosurg 100:303-309, 2004.
29. Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, Callaghan R, Collado M, Roldan P, Llombart-Bosch A: Association of loss of 1p and alterations of chromosome 14 in meningioma progression. Cancer Genet Cytogenet 148:123-128, 2004.
30. Loven D, Hardoff R, Sever ZB, Steinmetz AP, Gornish M, Rappaport ZH, Fenig E, Ram Z, Sulkes A: Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol 67:221-226, 2004.
31. Malham GM, Thomsen RJ, Synek BJ, Baguley BC: Establishment of primary human meningiomas as subcutaneous xenografts in mice. Br J Neurosurg 15:328-334, 2001.
32. Marks PA, Richon VM, Rifkind RA: Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216, 2000.
33. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE: Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 97:341-346, 2002.
34. McCutcheon IE: The biology of meningiomas. J Neurooncol 29:207-216, 1996.
35. McCutcheon IE, Friend KE, Gerdes TM, Zhang BM, Wildrick DM, Fuller GN: Intracranial injection of human meningioma cells in athymic mice: An orthotopic model for meningioma growth. J Neurosurg 92:306-314, 2000.
36. Medhkour A, Van Roey M, Sobel RA, Fingert HJ, Lee J, Martuza RL: Implantation of human meningiomas into the subrenal capsule of the nude mouse. A model for studies of tumor growth. J Neurosurg 71:545-550, 1989.
37. Newton HB, Scott SR, Volpi C: Hydroxyurea chemotherapy for meningiomas: Enlarged cohort with extended follow-up. Br J Neurosurg 18:495-499, 2004.
38. Ng HK, Wong AT: Expression of epithelial and extracellular matrix protein markers in meningiomas. Histopathology 22:113-125, 1993.
39. Pallini R, Casalbore P, Mercanti D, Maggiano N, Larocca LM: Phenotypic change of human cultured meningioma cells. J Neurooncol 49:9-17, 2000.
40. Palma L: Why do meningiomas recur? J Neurosurg Sci 47:65-68, 2003.
41. Perry A: Unmasking the secrets of meningioma: A slow but rewarding journey. Surg Neurol 61:171-173, 2004.
42. Perry A, Gutmann DH, Reifenberger G: Molecular pathogenesis of meningiomas. J Neurooncol 70:183-202, 2004.
43. Püttmann S, Senner V, Braune S, Hillmann B, Exeler R, Rickert CH, Paulus W: Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab Invest 85:1163-1171, 2005.
44. Radley MG, di Sant'Agnese PA, Eskin TA, Wilbur DC: Epithelial differentiation in meningiomas. An immunohistochemical, histochemical, and ultrastructural study - With review of the literature. Am J Clin Pathol 92:266-272, 1989.
45. Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, Sreedharen S, Keer H, Lum B, Scappaticci F, Bhatnagar A: Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45:381-386, 2004.
46. Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K, Diamantidis G, France D, Green MA, Howell KL, Kashi R, Kwon P, Lassota P, Martin MS, Mou Y, Perez LB, Sharma S, Smith T, Sorensen E, Taplin F, Trogani N, Versace R, Walker H, Weltchek-Engler S, Wood A, Wu A, Atadja P: N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: Discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl) ethyl]amino]methyl ]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem 46:4609-4624, 2003.
47. Russell DS, Rubinstein LJ: Tumours of the meninges and related tissues, in Russell DS, Rubinstein LJ (eds): Pathology of Tumours of the Nervous System. Baltimore, Williams & Wilkins, 1989, ed 5, pp 449-507.
48. Schrell UM, Rittig MG, Anders M, Kiesewetter F, Marschalek R, Koch UH, Fahlbusch R: Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg 86:845-852, 1997.
49. Simon M, Park TW, Leuenroth S, Hans VH, Loning T, Schramm J: Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression. J Neurosurg 92:832-840, 2000.
50. Stewart SA, Weinberg RA: Telomerase and human tumorigenesis. Semin Cancer Biol 10:399-406, 2000.
51. Theaker JM, Gatter KC, Esiri MM, Fleming KA: Epithelial membrane antigen and cytokeratin expression by meningiomas: An immunohistological study. J Clin Pathol 39:435-439, 1986.
52. Thiagalingam S, Cheng KH, Lee HJ, Mineva M, Thiagalingam A, Ponte JF: Histone deacetylases: Unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 983:84-100, 2003.
53. van Furth WR, Laughlin S, Taylor MD, Salhia B, Mainprize T, Henkelman M, Cusimano MD, Ackerly C, Rutka JT: Imaging of murine brain tumors using a 1.5 Tesla clinical MRI system. Can J Neurol Sci 30:326-332, 2003.
54. Weisberg E, Catley L, Kujawa J, Atadja P, Remiszewski S, Fuerst P, Cavazza C, Anderson K, Griffin JD: Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia 18:1951-1963, 2004.
55. Yazaki T, Manz HJ, Rabkin SB, Martuza RL: Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 55:4752-4756, 1995